Clinical Trials Logo

Filter by:
NCT ID: NCT03750812 Not yet recruiting - Physical Activity Clinical Trials

The Effect of Age, Physical Fitness and a Single Bout of Aerobic Exercise on Motor and Cognitive Functions

Start date: December 2018
Phase: N/A
Study type: Interventional

The proposed study is intended to examine the connection between two types of inhibition - cognitive and motor and the connection between motor inhibitory functions and a single bout of physical exercise in the context of age and physical fitness.

NCT ID: NCT03735134 Not yet recruiting - Clinical trials for Myocardial Infarction

Colchicine in Periprocedural Myocardial Infarction: the Role of Alpha Defensin

Start date: November 2018
Phase: N/A
Study type: Interventional

The aim of this research is to study the effect of a loading dose of colchicine on the occurrence of periprocedural myocardial infarction (PPMI) in elective percutaneous coronary intervention.

NCT ID: NCT03708809 Not yet recruiting - Contraception Clinical Trials

Immediate Versus Delayed Initiation of Intrauterine System

JANESS
Start date: December 1, 2023
Phase: N/A
Study type: Interventional

Contraception for teenagers and young adults presents a huge challenge for the clinician as more than half of all unintended pregnancies occur as a result of inconsistent or discontinued use of contraceptives . Possible solution is promoting the use of long acting reversible contraception, (LARC) among them the intrauterine device (IUD). IUD provide safe, highly effective, long-term contraception. Immediate IUD insertion after the termination of pregnancy (TOP) is a very convenient way to provide contraception as it is an opportune moment to carry out this short, easy, and safe procedure. Janess is a T-shaped intrauterine delivery system that was introduced lately, which slowly releases a small amount (13.5 mg) of levonorgestrel after its installation inside the womb and provides contraception for up to three years. The aim of this study to compare insertion of 13.5 mg levonorgestrel-releasing intrauterine system after surgical abortion immediately versus delayed insertion (at menstruation)

NCT ID: NCT03702959 Not yet recruiting - Hypoglycemia Clinical Trials

Antenatal Betamethasone and the Risk of Neonatal Hypoglycemia

Start date: October 1, 2018
Phase:
Study type: Observational [Patient Registry]

A single "supraphysiological" course of exogenous corticosteroids is recommended between 24-34 weeks' gestation to minimize the adverse sequelae associated with prematurity. The 24-hour profile of endogenous corticosteroids normally follows a diurnal rhythm with the highest serum level occurs between 5am-11am and nadir over 12 hours.

NCT ID: NCT03640416 Not yet recruiting - Stress Clinical Trials

The Feasibility to Use Wearable Devices to Collect Physiologic Data During Night Shifts - A Pilot Study

Start date: October 2018
Phase: N/A
Study type: Interventional

There is an increase interest in the use of wearable activity trackers and wearable technology in the various medical fields. Such devices can increase physical activity and decrease weight significantly. Field and laboratory studies have shown that shift work can alter circadian rhythms, disrupt the sleep cycle, and hinder human performance. Sleep deprivation reduces alertness level, and may increase reaction time, cause memory impairment and impaired motor skills. Disrupted circadian rhythms, a well-known consequence of atypical work schedules, have been linked to neurodegeneration. The aim of this pilot study is to evaluate the feasibility of wearable devices to collect data on physiologic parameters during sleep and awake under stress conditions. The study population will include 30 Rambam Health Care Campus medical residents who work nights on call. The length of experiment per participant will be one month. Subjective data on stress will be collected during the study. Data on vital signs and sleep stages will be collected through a smart watch Fitbit® Charge HR.

NCT ID: NCT03635398 Not yet recruiting - Procedural Sedation Clinical Trials

Intranasal Midazolam for Pediatric Pre-procedural Sedation and Pre-procedural Anti-anxiety Using sipNose Device - a Randomized Controlled Study

Start date: August 2018
Phase: N/A
Study type: Interventional

A Three-arm, Randomized Controlled Trial for Pediatric Pre-procedural Sedation and Pre-procedural Anti-anxiety: Intranasal Midazolam by SipNose versus MAD Versus oral administration

NCT ID: NCT03634293 Not yet recruiting - Sepsis Clinical Trials

Treatment of Severe Infection With Antihyperlipidemia Drug

Start date: January 2019
Phase: Phase 2/Phase 3
Study type: Interventional

Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors increase LDL receptors by decreasing its degradation. In sepsis the pathogenic substances, endotoxin, lipoteichoic acid, phospholipomannan are the main cause of the ongoing inflammation that causes the severe damage and outcome. these substances are removed from the blood by the LDL receptors. By administering PCSK9 inhibitors to patients with sepsis/septic shock this inflammatory response can be stopped and by doing so improve the patients outcome.

NCT ID: NCT03632564 Not yet recruiting - Clinical trials for Cerebral Arterial Diseases

Modulation of Brain Blood Flow Using Dichoptic Visual and Auditory Stimulation

Start date: October 10, 2018
Phase: N/A
Study type: Interventional

Modulation of brain blood flow using dichoptic Visual and Auditory stimulation using REVIVIEW system will be evaluated.

NCT ID: NCT03625518 Not yet recruiting - Clinical trials for Fetal Growth Retardation

Mode of Induction in Fetal Growth Restriction and Its Affects on Fetal and Maternal Outcomes

Start date: September 2018
Phase: Early Phase 1
Study type: Interventional

to compare methods of induction of labor in fetal growth restriction and its effect on maternal and neonatal outcome

NCT ID: NCT03604796 Not yet recruiting - Clinical trials for Ductus Arteriosus, Patent

Alternative Paracetamol Treatments for the Neonate With a hsPDA

Start date: September 2018
Phase: Phase 2/Phase 3
Study type: Interventional

Early targeted treatment of a hemodynamically significant patent ductus arteriosus (hsPDA) during the first week of life in preterm neonates is often recommended. Our standard first line therapeutic approach is enteral acetaminophen. However many extremely low birth weight infants may be on limited or no feeds when PDA closure is determined to be indicated, thus restricting the use of enteral acetaminophen. Several studies have suggested that intravenous acetaminophen is less effective than enteral. Thus, in this study, we propose to compare two alternative modes of administration when enteral acetaminophen is not an option.